Description: Clinuvel Pharmaceuticals Ltd is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With our unique expertise in understanding the interaction of light and human skin, we have identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million.
Home Page: www.clinuvel.com
535 Bourke Street
Melbourne,
VIC
3000
Australia
Phone:
61 3 9660 4900
Officers
| Name | Title |
|---|---|
| Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA | CEO, MD & Director |
| Mr. Darren M. Keamy | CFO & Company Sec. |
| Dr. Dennis J. Wright | Chief Scientific Officer |
| Mr. Lachlan Hay | Director of Global Operations |
| Mr. Malcolm Bull | Head of Investor Relations |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 56.3929 |
| Price-to-Book MRQ: | 8.2669 |
| Price-to-Sales TTM: | 10.6458 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |